.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,798,349

« Back to Dashboard

Claims for Patent: 5,798,349

Title: Use of green porphyrins to treat neovasculature in the eye
Abstract:Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions.
Inventor(s): Levy; Julia (Vancouver, CA), Miller; Joan W. (Boston, MA), Gradoudas; Evangelos S. (Boston, MA), Hasan; Tayyaba (Arlington, MA), Schmidt-Erfurth; Ursula (Luebeck, DE)
Assignee: The General Hospital Corporation (Boston, MA) Quadra Logic Technologies, Inc. (Vancouver, B.C., CA) Massachuesetts Eye & Ear Infirmary (Boston, MA)
Application Number:08/390,591
Patent Claims: 1. A method to treat conditions of the eye characterized by unwanted neovasculature, which method comprises:

administering to a primate subject in need of such treatment an amount of liposomal formulation of green porphyrin sufficient to permit an effective amount to localize in said neovasculature;

permitting sufficient time to elapse to allow an effective amount of said green porphyrin to localize in said neovasculature; and

irradiating the neovasculature with light from a laser, said light being absorbed by the green porphyrin so as to occlude said neovasculature.

2. The method of claim 1 wherein the neovasculature is choroidal neovasculature.

3. The method of claim 1 wherein the green porphyrin is of the formula shown in FIG. 1-3 or 1-4.

4. The method of claim 1 wherein said green porphyrin is of a formula shown in FIG. 1 or a mixture thereof

wherein each of R.sup.1 and R.sup.2 is independently selected from the group consisting of carbalkoxyl (2-6C), alkyl (1-6C), arylsulfonyl (6-10C), cyano and --CONR.sup.5 CO wherein R.sup.5 is aryl (6-10C) or alkyl (1-6C);

each R.sup.3 is independently carboxyl, carboxyalkyl (2-6C) or a salt, amide, ester or acyl hydrazone thereof, or is alkyl (1-6C);

R.sup.4 is --CH.dbd.CH.sub.2 or --CH(OR.sup.4')CH.sub.3 wherein R.sup.4' is H, or alkyl (1-6C) optionally substituted with a hydrophilic substituent.

5. The method of claim 4 wherein said green porphyrin is of the formula shown in FIG. 1-3 or 1-4 or a mixture thereof and wherein each of R.sup.1 and R.sup.2 is independently carbalkoxyl (2-6C);

one R.sup.3 is carboxyalkyl (2-6C) and the other R.sup.3 is the ester of a carboxyalkyl (2-6C) substituent; and

R.sup.4 is --CH.dbd.CH.sub.2 or --CH(OH)CH.sub.3.

6. The method of claim 5 wherein said green porphyrin is of the formula shown in FIG. 1-3 and wherein R.sup.1 and R.sup.2 are methoxycarbonyl;

one R.sup.3 is --CH.sub.2 CH.sub.2 COOCH.sub.3 and the other R.sup.3 is --CH.sub.2 CH.sub.2 COOH; and

R.sup.4 is --CH.dbd.CH.sub.2.

7. A method to treat unwanted choroidal neovasculature which method comprises

administering to a primate subject in need of such in need of such treatment an amount of green porphyrin sufficient to permit an effective amount to localize in said choroidal neovasculature;

permitting sufficient time to elapse to allow an effective amount of said green porphyrin to localize in said choroidal neovasculature; and

irradiating said choroidal neovasculature with light from a laser, said light being absorbed by the green porphyrin so as to occlude said neovasculature.

8. The method of claim 7 wherein said green porphyrin is complexed with low-density lipoprotein.

9. The method of claim 7 wherein said green porphyrin is contained in a liposomal preparation.

10. The method of claim 7 wherein the green porphyrin is of the formula shown in FIG. 1-3 or 1-4.

11. The method of claim 7 wherein said green porphyrin is of a formula shown in FIG. 1 or a mixture thereof

wherein each of R.sup.1 and R.sup.2 is independently selected from the group consisting of carbalkoxyl (2-6C), alkyl (1-6C), arylsulfonyl (6-10C), cyano and --CONR.sup.5 CO wherein R.sup.5 is aryl (6-10C) or alkyl (1-6C);

each R.sup.3 is independently carboxyl, carboxyalkyl (2-6C) or a salt, amide, ester or acyl hydrazone thereof, or is alkyl (1-6C);

R.sup.4 is --CH.dbd.CH.sub.2 or --CH (OR.sup.4') CH.sub.3 wherein R.sup.4' is H, or alkyl (1-6C) optionally substituted with a hydrophilic substituent.

12. The method of claim 11 wherein said green porphyrin is of the formula shown in FIG. 1-3 or 1-4 or a mixture thereof and wherein each of R.sup.1 and R.sup.2 is independently carbalkoxyl (2-6C);

one R.sup.3 is carboxyalkyl (2-6C) and the other R.sup.3 is the ester of a carboxyalkyl (2-6C) substituent; and

R.sup.4 is --CH.dbd.CH.sub.2 or --CH(OH)CH.sub.3.

13. The method of claim 12 wherein said green porphyrin is of the formula shown in FIG. 1-3 and

wherein R.sup.1 and R.sup.2 are methoxycarbonyl;

one R.sup.3 is --CH.sub.2 CH.sub.2 COOCH.sub.3 and the other R.sup.3 is --CH.sub.2 CH.sub.2 COOH; and

R.sup.4 is --CH.dbd.CH.sub.2.

14. A method to treat age-related macular degeneration (AMD) which method comprises

administering to a primate subject in need of such treatment an amount of green porphyrin sufficient to permit an effective amount to localize in the choroid;

permitting sufficient time to elapse to allow an effective amount of said green porphyrin to localize in said choroid; and

irradiating said choroid with light from a laser, said light being absorbed by the green porphyrin.

15. The method of claim 14 wherein said green porphyrin is complexed with low-density lipoprotein.

16. The method of claim 14 wherein said green porphyrin is contained in a liposomal preparation.

17. The method of claim 14 wherein the green porphyrin is of the formula shown in FIG. 1-3 or 1-4.

18. The method of claim 14 wherein said green porphyrin is of a formula shown in FIG. 1 or a mixture thereof

wherein each of R.sup.1 and R.sup.2 is independently selected from the group consisting of carbalkoxyl (2-6C), alkyl (1-6C), arylsulfonyl (6-10C), cyano and --CONR.sup.5 CO wherein R.sup.5 is aryl (6-10C) or alkyl (1-6C);

each R.sup.3 is independently carboxyl, carboxyalkyl (2-6C) or a salt, amide, ester or acyl hydrazone thereof, or is alkyl (1-6C);

R.sup.4 is --CH.dbd.CH.sub.2 or --CH(OR.sup.4') CH.sub.3 wherein R.sup.4' is H, or alkyl (1-6C) optionally substituted with a hydrophilic substituent.

19. The method of claim 18 wherein said green porphyrin is of the formula shown in FIG. 1-3 or 1-4 or a mixture thereof and wherein each of R.sup.1 and R.sup.2 is independently carbalkoxyl (2-6C);

one R.sup.3 is carboxyalkyl (2-6C) and the other R.sup.3 is the ester of a carboxyalkyl (2-6C) substituent; and

R.sup.4 is --CH.dbd.CH.sub.2 or --CH(OH)CH.sub.3.

20. The method of claim 19 wherein said green porphyrin is of the formula shown in FIG. 1-3 and

wherein R.sup.1 and R.sup.2 are methoxycarbonyl;

one R.sup.3 is --CH.sub.2 CH.sub.2 COOCH.sub.3 and the other R.sup.3 is --CH.sub.2 CH.sub.2 COOH; and

R.sup.4 is --CH.dbd.CH.sub.2.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc